The cooperation launched this spring at a working meeting between the Estonian Applied Research Centre and National Metrology Institute Metrosert and South Korea’s Gangwon Technopark has led to its first practical project. Together with South Korean technology company MENINBLOX, Metrosert will launch the field validation in Estonia of Roopin, an AI-powered solution that assesses runners’ training load and recovery. The aim of the project is to evaluate its performance among European users and prepare the solution for entry into the European Union market.
Developed by MENINBLOX, Roopin combines users’ running and injury histories with data collected from smartwatches, including activity, sleep efficiency and heart rate variability. Based on this information, the solution’s Ailix AI engine assesses runners’ daily condition and provides personalised recommendations on training load and rest. The application is intended to support users in making decisions related to training load and recovery, not to provide medical diagnoses.
According to the initial plan, the validation will involve 50 recreational runners in Estonia, who will use the solution for four weeks. The study will assess the application’s usability, adherence to its training and rest recommendations, and the extent to which the AI-generated recommendations correspond with the assessments of independent sports medicine experts.
According to Kaupo Reede, Member of the Management Board of Metrosert, the project presents an exciting challenge that combines expertise in evaluating AI models, the secure use of health data and applied research.
“The Health Data Unit of Metrosert’s Applied Research Centre was established to enable companies to use health data in developing their products and services. We help design studies and data flows, assess data quality and the performance of AI models, and ensure secure data processing. Our goal is to turn development work into reliable evidence on which companies can build their business, both in their domestic market and internationally,” said Reede.
According to MENINBLOX CEO Benjamin Park, obtaining an independent assessment of the solution in an environment that meets European data protection and quality requirements is essential for entering the European market.
“With health technologies, it is not enough for AI to perform well in the developer’s home market. Its performance must also be assessed among users with different backgrounds, habits and data, while ensuring that health data is used transparently and securely. As Estonia’s national applied research centre, Metrosert provides us with the independent expertise and reliable validation framework we need. The results of the cooperation will help us further develop Roopin and prepare the solution for entry into the European market,” said Park.
The project is funded under the South Korean Gangwon AI Healthcare Global Innovation Zone 2026 programme. The programme aims to support the international development of AI-powered health technologies created in the Gangwon region and help them enter new markets.
In March 2026, Metrosert and Gangwon Technopark held a working meeting to establish a framework for future cooperation, with a formal memorandum of understanding scheduled to be signed during a visit to Estonia this September. The aim of the cooperation is to support South Korean health technology companies in entering the European market. Gangwon Technopark brings together companies, hospitals and research institutions in the region and supports their technological development and international cooperation.
